Pathelen Hybrid is a medical device class 1 registered with the FDA. Pathelen Hybrid was developed by Pathelen Health Care AG in Switzerland specifically to treat chronic wounds such as pressure ulcer and diabetic foot ulcer that are non-healing and/or are suggested for amputation.
Registration and login required*
Pathelen Hybrid targets the biofilm which is the main reason, chronic wounds are not healing and removes the biofilm from the wound by adsorbing wound exudate. Pathelen Hybrid's mode of action is purely physical due to its non-pharmaceutical ingredients. Thus our product doesn't have any side effects. After a debridement Pathelen Hybrid is applied on the wound. If necessary the application can be repeated until granulation tissue is formed. This occurs generally between 5-10 days after application. As soon as the formation of granulation tissue is observed, the Pathelen Hybrid treatment is completed. A moist dressing should be administered on the wound until closure which happens generally between 6-8 weeks.